Jordan Johnson, Founding Partner at Bridge Oncology, Board Member at the National Association of Medication Access & Patient Advocacy (NAMAPA), Founder of The Healthcare Hub, and Founder of LegacybyImpact, shared on LinkedIn:
“Everyone is talking about the $8 billion Curium-Lantheus merger.
I think the market is missing the bigger story. This transaction isn’t simply about two companies combining. It is another clear signal that oncology is entering a new era-one where infrastructure will matter just as much as innovation.
For years, the conversation around theranostics has centered on the next radiopharmaceutical, the next FDA approval, or the next clinical breakthrough.
Those advances are incredibly important. But the organizations that lead the next decade won’t simply be those with access to the newest therapy.
They will be the organizations capable of delivering an entire pipeline of therapies through integrated operations, resilient supply chains, coordinated clinical workflows, and sustainable healthcare economics.
Theranostics is no longer just a nuclear medicine initiative. It is becoming an enterprise strategy.
Success will require oncology, pharmacy, nuclear medicine, finance, revenue cycle, supply chain, compliance, technology, and executive leadership to operate as one coordinated system.
That is exactly where we believe the industry is heading.At Bridge Oncology, we made a deliberate decision several years ago to build capabilities beyond traditional radiation oncology consulting.
Today, we work alongside health systems, cancer centers, industry partners, and investors to help design, implement, and optimize sustainable theranostics programs that are built not only for today’s therapies, but for the next generation of innovation. The future of oncology will not be defined solely by who develops the next breakthrough therapy.
It will be defined by who builds the infrastructure capable of delivering every breakthrough that follows.
I explore why this merger is such an important signal for the future of oncology in my latest article.
I’d be interested to hear how others see this evolving over the next five to ten years.”